Clinical Trials Browser

Biliary Tract Neoplasms

NCT03785873 2026-02-13

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Completed

34 enrolled 13 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT06219941 2026-02-12

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Phase 2 Recruiting

224 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Stomach Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Phase 2 Active not recruiting

48 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT07265674 2026-01-23

Beacon-BTC

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06428409 2026-01-22

MK-9999-02A

Phase 1/2 Recruiting

220 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT03044587 2025-10-01

NIFE

Phase 2 Completed

93 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05489211 2025-07-11

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2 Recruiting

582 enrolled

GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03406299 2025-05-22

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2 Completed

92 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Phase 2/3 Not yet recruiting

206 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05116891 2023-07-03

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Phase 1/2 Completed

40 enrolled

GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03524508 2022-08-24

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

Phase 2 Completed

178 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03110510 2022-06-15

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT03778593 2021-02-04

FOLFIRINOX for 2nd-line Treatment of BTC

Phase 2 Completed

34 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT01926236 2020-01-28

ABC06

Phase 3 Completed

162 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03668418 2018-09-12

xenoZ

Unknown

120 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT01572324 2017-01-04

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas

Phase 2 Completed

37 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT01127555 2013-10-08

Salvage mFOLFOX in BTC After Failure of Gemcitabine

Phase 2 Completed

30 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT01494363 2011-12-19

Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2 Unknown

53 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT00090025 2009-01-14

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors

Phase 3 Terminated

248 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Clinical Trials

CROCOBIL

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Beacon-BTC

MK-9999-02A

NIFE

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

SAIB

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

FOLFIRINOX for 2nd-line Treatment of BTC

ABC06

xenoZ

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas

Salvage mFOLFOX in BTC After Failure of Gemcitabine

Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer

XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors